OvaScience Inc. (NASDAQ:OVAS) saw unusually-strong trading volume on Thursday . Approximately 290,879 shares were traded during trading, a decline of 1% from the previous session’s volume of 295,308 shares.The stock last traded at $6.38 and had previously closed at $6.09.

A number of equities analysts recently commented on the company. Credit Suisse Group AG restated a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Wednesday, August 10th. JMP Securities restated a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. JPMorgan Chase & Co. decreased their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Friday, August 5th. Finally, Leerink Swann restated a “hold” rating and set a $7.00 target price (up previously from $6.00) on shares of OvaScience in a report on Sunday, May 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. OvaScience presently has a consensus rating of “Hold” and an average price target of $10.98.

The stock has a 50-day moving average price of $5.70 and a 200-day moving average price of $7.10. The stock’s market capitalization is $229.37 million.

OvaScience (NASDAQ:OVAS) last posted its earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.16. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. During the same period last year, the business earned ($0.64) EPS. OvaScience’s revenue was up 530.0% compared to the same quarter last year. Analysts forecast that OvaScience Inc. will post ($2.66) EPS for the current year.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.